(RTTNews) - Novo Nordisk and Evotec have selected three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center for development ...

LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three projects and launched an expansion featuring five new academic partners.

Evotec and Novo Nordisk launched LAB eN² in September 2023 with four academic institutions, Harvard University, Mass General Brigham, Yale School of Medicine, and Beth Israel Deaconess Medical ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

“We are thrilled to be able to start work on these first projects, leveraging Evotec’s integrated drug discovery and translational platforms and Novo Nordisk’s deep disease understanding,” said Dr ...

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² ...

First three selected projects will focus on research for different cardiometabolic conditions.

The issuer is solely responsible for the content of this announcement. Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General ...

Evotec and Novo Nordisk launched LAB eN² in September 2023 together with four academic institutions, Harvard University, Mass General Brigham, Yale School of Medicine, and Beth Israel Deaconess ...